Refine by
Bone Tumor Articles & Analysis
7 news found
Denosumab is an antibody treatment that shows a strong bone resorption inhibitory effect by targeting the RANKL protein, which is essential for the survival and function of osteoclasts. The original products are Amgen’s osteoporosis treatment Prolia (denosumab 60 mg), a treatment to prevent skeletal complications, and XGeva (denosumab 120 mg), a treatment for giant cell ...
Radiopharmaceuticals are radioactive agents that are utilized for the diagnosis of infection, vessel-related diseases, bone/bone marrow diseases, tumors, and other diseases in heart, lung, kidney, liver etc. ...
Based on the persistence of cells in the peripheral blood and bone marrow up to 18 months we conclude that Temferon successfully engrafts, and no drug-limiting toxicities have been identified. The ability of Temferon cells to find their way from bone marrow to the tumor site is supported by the presence of gene-marked cells in the ...
“So far, our combination technology has, in preclinical studies, demonstrated its ability to resolve existing metastatic bone lesions, inhibit pain and stimulate targeted bone regeneration. ...
Previously known as ZetaFuse™, ZetaMet™ is a synthetic, small-molecule, inductive biologic technology being developed to target and resolve metastatic bone lesions while inhibiting future tumor growth and regenerating bone. ...
Examples of organ models available at TissUse include the liver, intestine, skin, vasculature, neuronal tissue, cardiac tissue, cartilage, pancreas, kidney, thyroid, hair follicle, lung tissue, fatty tissue, tumor models, and bone marrow. Further organ models are being developed. ...
Osteoid osteoma is a non-cancerous bone tumor that occurs most often in the long bones of the leg, such as the femur and tibia, of young children and adolescents. ...